ClinicalTrials.gg
CompletedNCT06670534Updated Aug 10, 2026

A Dose-finding Study of JMKX003142 in Treatment of Renal Edema

A Phase 2 interventional study of JMKX003142 tablets and Placebo Tablets in Edema Secondary and Edema Leg, sponsored by Jemincare. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Jemincare · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Edema with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Edema · China.

Enrollment
5th of 10
133 · median 117
Started
2025
with 2 others
Phase 2
Only one
of the 11
Registered
8th of 11
by date
Lead sponsor
2 of 11
Jemincare

Among the 11 studies in Edema with a site in China, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 2, and was the 8th registered.

Edema

568 studies on the registry are indexed under Edema; 97 are open to participants now.

Browse Edema studies →

Open to participants now

4 of the 11 studies in Edema with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Edema with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety,efficacy, and pharmacokinetic characteristics of JMKX003142 administered randomly, double-blind, placebo-controlled study in Chinese renal edema patients with inadequate response to conventional diuretic therapy.

Read the detailed description

JMKX003142 is an arginine vasopressin(AVP)-V2R antagonist which shows a remarkable diuretic effect in healthy volunteers.In this phase 2 study ,we will observe the safety 、efficacy and pharmacokinetic(PK) characteristics about different dose levels of JMKX003142 tablets in renal edema who have an inadequate response to conventional diuretic therapy. This phase 2 study is designed as a randomly, double-blind,placebo-controlled study.

03

Conditions studied

  • Edema Secondary
  • Edema Leg

Browse trials for

Keywords

  • renal edema
  • edema due to kidney diseases
  • Diuretic resistance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who can fully understand the purpose and process of the study and voluntarily sign the form(ICF);
  • Age ≥ 18 years old during screening;
  • Diagnosed as renal edema during screening;
  • Estimated (eGFR) ≥ 15 mL/min/1.73m2 during screening.
  • At the start of the run-in period,patients must have been receiving either a loop diuretic at a dose equivalent to ≥40 mg of furosemide or a combination of any dose of a loop diuretic with a diuretic of another class (different mechanism of action).
  • Body weight change of \<1.0 kg during the run-in period.No changes in the conventional diuretic regimen during the run-in period.

Exclusion criteria

Exclusion Criteria:

  • Patients who are receiving the renal replacement therapy during screening or patients who require renal replacement therapy in the short term evaluated by the researchers;
  • Patients who are suspected with hypovolemia;
  • Patients with the following diseases or symptoms: acute thrombosis, diarrhea, and difficulty urinating;
  • Patients who are unable to sense thirst or who have difficulty with fluid intake;
  • Patients who have received arginine vasopressin-V2R blockers within 30 days prior to the screening examination;
  • The following laboratory indicators are abnormal: glutamic pyruvic transaminase ≥ 1.5 ×, glutamic oxaloacetic transaminase ≥ 1.5 × upper limit of normal, serum sodium> upper limit of normal;
  • Patients who received diuretics or treatments with diuretic effects from Day-2 to randomization;
  • During screening, systolic blood pressure \<90mmHg/diastolic blood pressure\<60mmHg, systolic blood pressure≥180 mmHg/diastolic blood pressure ≥110mmHg;
  • Patients who have a history of allergies to ≥ 3 substances, or are currently in an allergic state;
  • Female patients who are breast-feeding or who have a positive pregnancy test result prior to receiving product (IMP);
  • Sexually active males or women of (WOCBP) who do not agree to practice or remain abstinent during the trial and for 30 days after the final IMP administration.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    low dose group

    low dose of JMKX003142 tablets,take orally once daily,last for 7 days

    Drug: JMKX003142 tablets

  • Experimental
    high dose group

    high dose of JMKX003142 tablets,take orally once daily,last for 7 days

    Drug: JMKX003142 tablets

  • Placebo comparator
    Matched group

    placebo take orally once daily,last for 7 days

    Drug: Placebo Tablets

Interventions

  • JMKX003142 tablets for experimental groups.Take the JMKX003142 tablets once daily(one hour after meals)for seven days.

  • DrugPlacebo Tablets

    Placebo tablets for matched group.Take the placebo tablets once daily (one hour after meals)for seven days.

06

What researchers measure

Primary outcomes

  1. body weight

    Time frame: Day 8

Secondary outcomes

  1. 24-hour urine volume

    Time frame: Day 1 to day 7

  2. Bodyweight

    Time frame: Day 2 to day 7

  3. Improvement rate of edema in both lower limbs

    Time frame: Day 8

  4. Adverse events,vital signs,physical examination

    Time frame: Throughout the entire experimental period

  5. PK parameter

    Time frame: Day 1、2、6 and 7

07

Study locations

2 sites
  • Fudan University Affiliated Zhongshan Hospital
    Shanghai, 200102, China
  • Zhejiang Hangyu Pharmaceutical Co., Ltd(subsidiary of Jemincare)
    Shanghai, 200102, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Apr 2026, 6 months.

Of 14 phase 2 interventional studies under Edema, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 1, 2024
StartActual
Oct 17, 2025
Primary completionActual
Apr 27, 2026
CompletionActual
May 12, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06670534
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Oct 17, 2025
Primary completion
Apr 27, 2026
Completion
May 12, 2026
Last update
Aug 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JMKX003142

Start the discussion